Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Pharmac Commits To Being More Transparent

For the first time, Pharmac is sharing its priority lists for all funding applications for medicines it has assessed but not yet funded.

Pharmac’s Chief Executive Sarah Fitt explains, “Until now, we have not shared what applications were on which list, as we thought it could make it harder for us to negotiate with suppliers for the best deals. But we know people are interested in what applications we are actively considering and we want to be more transparent.

“As a government entity, it’s important that we are as open as we can be. This includes letting people know where funding applications are at in the Pharmac process.”

To provide a complete view of the applications Pharmac has completed its assessment of but not yet funded, the agency is sharing its three priority lists.

The options for investment list includes all the applications that would be funded if Pharmac had the budget for them. At the time of release, there are 102 applications on this list covering 71 medicines and related products.

Some applications on this list are for new medicines and some are for medicines already funded that Pharmac would like to fund for wider use for more patients. The preferential ranking Pharmac gives to applications on this list is determined using Pharmac’s decision-making framework, the Factors for Consideration.

“We think more widely than just the individual patient and the cost of the medicine,” says Sarah.

“We need to understand the full effect our decisions would have. Our expert advisers help us with the clinical aspects and our health economists identify the benefits and costs to the whole health system, patients, and their whānau.

“Our options for investment list is published in alphabetical order to keep the preferential rankings of individual funding applications confidential. This will ensure we can continue to negotiate the best prices we can for the medicines we can afford.

“If pharmaceutical companies knew how much we wanted to fund a medicine, it could make it harder for us to negotiate the best deal possible.”

The only if cost neutral or cost saving list includes applications that may get funded if Pharmac can negotiate a deal that saves money, or at least doesn't cost more.

“Our clinical experts help us assess whether an application delivers more benefits than treatments we already fund. If they think a treatment would not deliver better health outcomes than those already available, it is generally placed on our cost neutral or cost saving list.”

Pharmac doesn’t rank applications on this list in preferential order. It will consider negotiations with any supplier who offers cost neutral or cost saving pricing.

The recommended for decline list generally includes applications that Pharmac’s expert clinical advisors have suggested Pharmac turns down. Often this is because these medicines would add no value or are harmful. Pharmac does not actively work on these applications.

“People should have more certainty of information about applications, even if this is a decision to decline funding,” says Sarah.

“To make our approach clearer, we have been working through this list to formally decline a number of items on it.”

These three priority lists help Pharmac compare and make decisions on the 85 or so funding applications it receives every year.

“Every year, our fixed budget must pay for all the medicines that are already funded. If there is money left over or we receive a budget increase, we use this to fund new medicines or widen access to treatments we already fund.

If a funding application is not on one of the priority lists, it is still under assessment.

“We work hard to negotiate some of the best prices for medicines in the world and we follow a rigorous process to ensure all applications are thoroughly and fairly assessed.

“By making our lists easily available, we hope that New Zealanders will have more clarity about where applications are at that we have completed our assessment of but are not yet funded.”

See the priority lists online in Application Tracker:

© Scoop Media

Business Headlines | Sci-Tech Headlines


Consumer NZ: Buy-now, Pay-later Raking In $10m+ In Late Fees Annually

A Consumer NZ survey has found buy-now, pay-later services are costing shoppers more than $10 million a year in late fees. Close to four out of 10 Kiwi consumers use buy-now, pay-later services, such as Afterpay, Laybuy and Zip... More>>

Westpac: Catherine Mcgrath Appointed New Zealand CEO

Westpac Group CEO Peter King and the Westpac New Zealand Board today announced the appointment of Catherine McGrath as Chief Executive Officer, Westpac New Zealand... More>>

Amazon: AWS To Open Data Centres In New Zealand

Today, Amazon Web Services (AWS), announced plans to open an infrastructure region in Aotearoa New Zealand in 2024. The new AWS Asia Pacific (Auckland) Region will consist of three Availability Zones (AZs) and join the existing 81 Availability Zones across 25 geographic AWS Regions at launch... More>>


Statistics: Surge In Imports Results In Record Monthly Trade Deficit
Imports increased $1.8 billion in August 2021 compared with August 2020, resulting in a record monthly trade deficit of $2.1 billion, Stats NZ said today. Exports were little changed, down $42 million. "This is a larger deficit than normal because of higher values for imports.. More>>

Fonterra: Completes reset, announces annual results and long-term growth plan out to 2030

Fonterra Co-operative Group Limited today announced a strong set of results for the 2021 financial year, reflected in a final Farmgate Milk Price of $7.54, normalised earnings per share of 34 cents and a final dividend of 15 cents... More>>

Statistics: GDP rises in the June 2021 quarter

Gross domestic product (GDP) rose by 2.8 percent in the June 2021 quarter, following a 1.4 percent increase in the March 2021 quarter, Stats NZ said today. June 2021 quarter GDP was 4.3 percent higher when compared with the December 2019 quarter... More>>